Cargando…
Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood–brain barrier
NaCT/SLC13A5 is a Na(+)-coupled transporter for citrate in hepatocytes, neurons, and testes. It is also called mINDY (mammalian ortholog of ‘I'm Not Dead Yet’ in Drosophila). Deletion of Slc13a5 in mice leads to an advantageous phenotype, protecting against diet-induced obesity, and diabetes. I...
Autores principales: | Kopel, Jonathan J., Bhutia, Yangzom D., Sivaprakasam, Sathish, Ganapathy, Vadivel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868109/ https://www.ncbi.nlm.nih.gov/pubmed/33544126 http://dx.doi.org/10.1042/BCJ20200877 |
Ejemplares similares
-
Functional analysis of a species-specific inhibitor selective for human Na(+)-coupled citrate transporter (NaCT/SLC13A5/mINDY)
por: Higuchi, Kei, et al.
Publicado: (2020) -
A home run for human NaCT/SLC13A5/INDY: cryo-EM structure and homology model to predict transport mechanisms, inhibitor interactions and mutational defects
por: Jaramillo-Martinez, Valeria, et al.
Publicado: (2021) -
Unconventional Functions of Amino Acid Transporters: Role in Macropinocytosis (SLC38A5/SLC38A3) and Diet-Induced Obesity/Metabolic Syndrome (SLC6A19/SLC6A14/SLC6A6)
por: Bhutia, Yangzom D., et al.
Publicado: (2022) -
The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin
por: Kopel, Jonathan, et al.
Publicado: (2020) -
Plasma Membrane Na(+)-Coupled Citrate Transporter (SLC13A5) and Neonatal Epileptic Encephalopathy
por: Bhutia, Yangzom D., et al.
Publicado: (2017)